The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Growth Is Projected For The Huntington’s Disease Treatment Market During The Forecast Period 2026–2030?
The Huntington’s disease treatment market has witnessed rapid growth in recent years. It is projected to expand from $0.82 billion in 2025 to $0.92 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.6%. The historical surge in this market can be attributed to several factors: restricted treatment options for neurodegenerative disorders, an increased rate of diagnosis for genetic neurological diseases, an early focus on symptomatic management, the widening availability of neurology specialty care, and an expansion in hospital-based neurological treatments.
The Huntington’s disease treatment market is poised for substantial growth in the upcoming years. It is expected to reach $1.48 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.6%. This anticipated expansion during the forecast period is fueled by advancements in gene therapy technologies, increasing investment in rare disease research, a rise in orphan drug designations, the growing adoption of precision medicine, and an expanding pipeline of disease-modifying therapies. Dominant trends during this period encompass an increasing focus on disease-modifying treatments, broader integration of gene and RNA-based therapies, the proliferation of combination therapy approaches, an elevated emphasis on symptom-specific drug development, and increased clinical trial activity for rare neurological disorders.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24245&type=smp
What Underlying Factors Are Accelerating The Growth Of The Huntington’s Disease Treatment Market?
The growing availability of gene therapies is anticipated to drive the expansion of the Huntington’s disease treatment market moving forward. These treatments involve modifying or replacing faulty genes to address or prevent diseases at their genetic origin. Gene therapies are advancing due to developments in precision medicine, allowing for the direct targeting of genetic causes and leading to improved outcomes compared to conventional treatments. In the context of Huntington’s disease, gene therapies function by silencing the defective HTT gene responsible for producing harmful proteins, thereby preventing damage to nerve cells. This approach aids in slowing disease progression, preserving brain function, and offers potential for long-term control. For example, in July 2023, reports from the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, showed that 247 gene therapies were in phase II at the end of Q1 2023, a figure that climbed by 5% to 260 by the end of Q2. Thus, the rise in gene therapies is fueling the growth of the Huntington’s disease treatment market.
What Market Segments Are Evaluated Within The Huntington’s Disease Treatment Market?
The huntington’s disease treatment market covered in this report is segmented –
1) By Treatment: Symptomatic Treatment, Disease-Modifying Therapies
2) By Administration Type: Oral, Intravenous, Subcutaneous, Topical
3) By Therapeutic: Genetic Disorders, Neurological Disorders, Psychiatric Disorders
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Clinics, Homecare Settings, Research Centers
Subsegments:
1) By Symptomatic Treatment: Antidepressants, Antipsychotics, Mood Stabilizers, Chorea Medications, Cognitive Enhancers
2) By Disease-Modifying Therapies: Gene Therapy, Neuroprotective Agents, RNA-Based Therapies, Stem Cell Therapy, Protein-Targeting Therapies
What Industry Trends Are Redefining The Huntington’s Disease Treatment Market?
Leading companies in the Huntington’s disease treatment market are concentrating on developing advanced therapies, such as selective vesicular monoamine transporter 2 (VMAT2) inhibitor capsules, to potentially enhance patient quality of life while slowing disease progression. Selective VMAT2 inhibitor capsules are medications designed to block the vesicular monoamine transporter 2, a protein instrumental in packaging neurotransmitters for brain release. These drugs aid in reducing neurotransmitter release, thereby assisting in the management of involuntary movements and related symptoms. For example, in August 2023, Neurocrine Biosciences, Inc., a US-based biotech company, obtained approval from the U.S. Food and Drug Administration (FDA) for Ingrezza (valbenazine) capsules, indicated for the treatment of chorea associated with Huntington’s disease (HD) in adults. These capsules represent a once-daily oral VMAT2 inhibitor that functions by decreasing excessive dopamine signaling in the brain to help regulate involuntary movements. The medication is accessible in various capsule strengths and can be consumed with or without food, presenting a convenient dosing alternative for patients.
Who Are The Top Market Participants Influencing The Huntington’s Disease Treatment Market?
Major companies operating in the huntington’s disease treatment market are F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Neurocrine Biosciences Inc., Wave Life Sciences Ltd., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., uniQure N.V., Prilenia Therapeutics B.V., Sage Therapeutics Inc., Annexon Inc., Alnylam Pharmaceuticals Inc., Sun Pharmaceutical Industries Inc., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Hikma Pharmaceuticals plc, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., AbbVie Inc.
Read the full huntington’s disease treatment market report here:
https://www.thebusinessresearchcompany.com/report/huntingtons-disease-treatment-global-market-report
Which Region Is Projected To Dominate The Huntington’s Disease Treatment Market During The Forecast Period?
North America was the largest region in the Huntington’s disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington’s disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Huntington’s Disease Treatment Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24245&type=smp
Browse Through More Reports Similar to the Global Huntington’s Disease Treatment Market 2026, By The Business Research Company
Brain Tumor Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report
Brain And Neuroimaging Devices Market Report 2026
Brain Tumor Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model